

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

Acumen Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

00509G209

(CUSIP Number)

July 1, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for the information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934.

CUSIP No. 00509G209

(1) Name of Reporting Person: Molly G. Hardie

(2) Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

(3) SEC Use Only

(4) Citizenship or Place of Organization: United States of America

Number of Shares Beneficially Owned by Each Reporting Person With:

(5) Sole Voting Power: 0

(6) Shared Voting Power: 3,451,152

(7) Sole Dispositive Power: 0

(8) Shared Dispositive Power: 3,451,152

(9) Aggregate Amount Beneficially Owned by Reporting Person: 3,451,152

(10) Check box if the aggregate amount in row (9) excludes certain shares (See Instructions):

(11) Percent of class represented by amount in row (9): 8.5%

(12) Type of Reporting Person (See Instructions): IN, HC

CUSIP No. 00509G209

(1) Name of Reporting Person: Robert D. Hardie

(2) Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

(3) SEC Use Only

(4) Citizenship or Place of Organization: United States of America

Number of Shares Beneficially Owned by Each Reporting Person With:

(5) Sole Voting Power: 0

(6) Shared Voting Power: 3,451,152

(7) Sole Dispositive Power: 0

(8) Shared Dispositive Power: 3,451,152

(9) Aggregate Amount Beneficially Owned by Reporting Person: 3,451,152

(10) Check box if the aggregate amount in row (9) excludes certain shares (See Instructions):

(11) Percent of class represented by amount in row (9): 8.5%

(12) Type of Reporting Person (See Instructions): IN, HC

SCHEDULE 13G

Item 1(a) Name of Issuer: Acumen Pharmaceuticals, Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:
427 Park Street, Charlottesville, Virginia 22902

Item 2(a) Name of Persons Filing:

Level One Partners, LLC and H7 Holdings, LLC (the "Affiliate Entities") each directly owns a portion of the shares reported in this schedule ("Schedule"). This S

Item 2(b) Address of Principal Business Office or, if None, Residence:

Molly G. Hardie
210 Ridge McIntire Road, Suite 350
Charlottesville, Virginia 22903

Robert D. Hardie
210 Ridge McIntire Road, Suite 350
Charlottesville, Virginia 22903

Item 2(c) Citizenship:

Robert D. Hardie - United States of America
Molly G. Hardie - United States of America

Item 2(d) Title of Class of Securities:

Common Stock, par value \$0.0001

Item 2(e) CUSIP No.: 00509G209

Item 3 If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Act;
(b) Bank as defined in Section 3(a)(6) of the Act;
(c) Insurance company as defined in Section 3(a)(19) of the Act;
(d) Investment company registered under Section 8 of the Investment Company Act of 1940;
(e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
(j) A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
(k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please

Item 4 Ownership

Item 4(a) Amount Beneficially Owned:

Molly G. Hardie - 3,451,152
Robert D. Hardie - 3,451,152

Item 4(b) Percent of Class:

Molly G. Hardie - 8.5%
Robert D. Hardie - 8.5%

Item 4(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

Molly G. Hardie - 0
Robert D. Hardie - 0

(ii) Shared power to vote or to direct the vote:

Molly G. Hardie - 3,451,152
Robert D. Hardie - 3,451,152

(iii) Sole power to dispose or to direct the disposition of:

Molly G. Hardie - 0
Robert D. Hardie - 0

(iv) Shared power to dispose or to direct the disposition of:

Molly G. Hardie - 3,451,152
Robert D. Hardie - 3,451,152

Item 5 Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent

Item 6 Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8 Identification and Classification of Members of the Group.

Not applicable.

Item 9 Notice of Dissolution of Group.

Not applicable.

Item 10 Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, c

Dated: February 16, 2022

/s/ Molly G. Hardie
Molly G. Hardie

/s/ Robert D. Hardie
Robert D. Hardie

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on beha

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree as follows:

- (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each o

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the inf

Dated: February 16, 2022

/s/ Molly G. Hardie
Molly G. Hardie

/s/ Robert D. Hardie
Robert D. Hardie